0001171843-17-004625.txt : 20170802 0001171843-17-004625.hdr.sgml : 20170802 20170802170154 ACCESSION NUMBER: 0001171843-17-004625 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170728 FILED AS OF DATE: 20170802 DATE AS OF CHANGE: 20170802 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GOLDENBERG DAVID M CENTRAL INDEX KEY: 0001029578 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12104 FILM NUMBER: 171001014 MAIL ADDRESS: STREET 1: UBS GLOBAL ASSET MANAGEMENT (US) INC. STREET 2: 51 WEST 52ND STREET CITY: NEW YORK STATE: NY ZIP: 10019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOMEDICS INC CENTRAL INDEX KEY: 0000722830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 611009366 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 300 AMERICAN RD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 BUSINESS PHONE: 9736058200 MAIL ADDRESS: STREET 1: 300 AMERICAN ROAD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 4 1 f4_dgoldenberg080217.xml OWNERSHIP DOCUMENT X0306 4 2017-07-28 0 0000722830 IMMUNOMEDICS INC IMMU 0001029578 GOLDENBERG DAVID M C/O IMMUNOMEDICS, INC 300 THE AMERICAN ROAD MORRIS PLAINS NJ 07950 1 1 0 0 See Remarks Common Stock 2017-07-28 4 A 0 4874 0 A 2405928 D Common Stock 2017-07-28 4 F 0 1950 8.75 D 2403978 D Common Stock 2017-07-28 4 A 0 4873 0 A 3472296 I See Footnote Represents the settlement of common stock underlying Performance Units that have vested in accordance with the terms of the Performance-Based Restricted Stock Unit Agreement entered into on August 16, 2013 by and between the Company and each of the reporting person and his spouse, Ms. Cynthia L. Goldenberg, a director of the Company. Includes a total of 190,000 shares held as joint tenants by the reporting person and Ms. Goldenberg. Such shares are held by the reporting person's spouse, by various trusts established for the benefit of the reporting person and/or family members of the reporting person, or by a majority-owned subsidiary of the Issuer, of which the reporting person is an officer. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interests therein. Chief Scientific Officer and Chief Patent Officer /s/ Cynthia L. Sullivan, Attorney-In-Fact 2017-08-02